Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
Advances in Rheumatology, cilt.60, sa.1, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 60 Sayı: 1
- Basım Tarihi: 2020
- Doi Numarası: 10.1186/s42358-020-0117-1
- Dergi Adı: Advances in Rheumatology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Anahtar Kelimeler: Anakinra, Canakinumab, Familial Mediterranean fever (FMF), Amyloidosis, Colchicine-resistant, ANTI-IL-1 TREATMENT, RECOMMENDATIONS, MANAGEMENT, SECONDARY, THERAPY
- Sivas Cumhuriyet Üniversitesi Adresli: Evet
Özet
Introduction: Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) treatments are recommended in colchicine resistant and/or intolerant FMF patients. This study aims to evaluate the efficacy of anakinra and canakinumab in FMF patients that are resistant/intolareted to colchicine or complicated with amyloidosis.